319 results about "Lactobacillus gasseri" patented technology

The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E.Coli, Gemmiger, Desullomonas, Peptostreptococcus, and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli, at least one strain of viable non-pathogenic or attenuated pathoenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.

The invention relates to a probiotic combination comprising different combinations of lactobacilli. propionic acid bacteria and/or bifidobacteria. The probiotics are preferably combined with a suitable prebiotic to form a synbiotic. The combination of the invention can be consumed as such or combined with a suitable foodstuff or pharmaceutical product, and it is therapeutically useful for example for stimulating the immune system and for general health improvement.

A composition for restoring and maintaining gastrointestinal health comprises 40-60% by weight of an immunoglobulin composition comprising concentrated immunologically active immunoglobulins and 40-60% by weight of soluble dietary fiber selected from inulin, fructo-oligosaccharides, pectin, guar gum, and mixtures thereof. The immunoglobulin and fiber-containing composition can optionally contain one or more of a beneficial human intestinal microorganism, components of a non-immune natural defense system, an iron-sequestering molecule, and gluconic acid. Preferred beneficial human intestinal microorganisms include lactobacilli and bifidobacteria. The immunologically active immunoglobulins are preferably purified from bovine milk, milk products, or whey. Methods of use are also described.

Strains of Lactobacillus that have been selected for their capability of reducing the number of Streptococcus mutans in the mouth of mammals through inhibiting activity in combination with good binding to the oral mucins and dental plaque, Administering the strains in a product such as food, reduces and treats dental caries. Preferred strains are Lactobacillus reuteri strain ATTC PTA-4965 or Lactobacillus reuteri strain ATTC PTA-4964.

The invention discloses two lactobacillus separation strains with anti-inflammatory activity and beneficial properties, which are Lactobacillus sakei GMNL-76 and Lactobacillus reuteri GMNL-89. The two lactobacillus separation strains are respectively preserved in the Bioresouce Collection and Research Center (BCRC) of the Food Industry Research and Development Institute (FIRDI) by preservation numbers of BCRC 910355 and BCRC 910340 and preserved in the China Center for Type Culture Collection (CCTCC) by the preservation numbers of CCTCC M 207153 and CCTCC M 207154. The two lactobacillus separation strains and subculture offspring thereof can be used for preparing various food products and pharmaceutical composition for curing and/or mitigating diseases (such as rheumatoid arthritis) relevant to inflammation.

The invention discloses two Lactobacillus isolated strains with anti-inflammatory activity and beneficial probiotic characteristics, namely lactobacillus sakei GMNL-76 and Lactobacillus reuteri GMNL-89, which are respectively preserved at the Bioresource Collection and Research Center (BCRC) of the Food Industry Research and Development Institute (FIRDI) with the preservation numbers of BCRC 910355 and BCRC 910340, and preserved at the China Center for Type Culture Collection (CCTCC) with the preservation numbers of CCTCC M 207153 and CCTCC M 207154. The two Lactobacillus isolated strains and subculture progeny thereof can be used for preparing various food products, and drug composites used for curing and/or relieving diseases related to inflammation, such as rheumatoid arthritis.

The invention discloses a lactobacillus leavening agent, a preparation method thereof and a special bacterial strain. The preservation serial number of lactobacillus is CCTCC M208151. An active constituent of the lactobacillus leavening agent is the lactobacillus. The invention also discloses a method for preparing the lactobacillus leavening agent, which comprises the following steps: firstly, leavening and culturing lactobacillus plantarum SC79 CCTCC M208151 in SC79 optimal culture medium; and secondly, collecting thallus in the step 1 and then adding a protective agent to the thallus to obtain the leavening agent. The lactobacillus leavening agent has small dosage, quick acid production speed through mixing the lactobacillus leavening agent and a harvestless exopolysacchatide yoghourt bacterial strain to prepare yoghourt, better relative viscosity, elasticity, denseness and adhesiveness than that of the conventional yogurt and small syneresis sensibility of formed sticky yogurt colloids, larger water holding capacity than that the conventional yogurt and hard whey separation.

The invention relates to new isolated Lactobacillus and Bifidobacterium strains which have been isolated from fresh honey having a water content above 18% by weight or from the honey producing tract of at least one bee. The bacterial strains have unique properties rendering them useful in many products such as in food and beverage products, feed products and medica products.

Present invention features a novel use of Lactobacillus for treating type 2 diabetes, wherein the Lactobacillus is Lactobacillus reuteri GMNL-89 with the deposition numbers of BCRC 910340 and CCTCC M 207154 and comprises of live, dead bacteria or supernatant of the bacterial culture(s) and a pharmaceutically acceptable vehicle. The invention also discloses the efficacies of the indicated Lactobacillus strain including anti-oxidative enzyme activity, anti-inflammation, reduction of blood glucose level, reduction of triglycerides, reduction of total cholesterol, reduction of LDL, increase of HDL and improve insulin utilization.

Disclosed herein are probiotic compositions comprising a mixture of at least two probiotic bacteria, including Streptococcus salivarius K12® (BLIS K12®) and at least a Lactobacillus bacteria. The Streptococcus salivarius K12® (BLIS K12®) may comprise Streptococcus salivarius K12® (BLIS K12®) BAA1024. The Lactobacillus bacteria may be selected from those known to be suitable for oral administration, for example from those known to improve recipient health, particularly recipient oral health.

The present invention provides lactic acid bacteria which are suitable for use for dietary products and pharmaceuticals, and which can suppress the increase of blood uric acid level.

Various types of lactic acid bacteria were cultured in the presence of a purine, the amount of the purine consumed and the amount of purine degradation products produced were measured, and several lactic acid bacteria showing remarkable purine-decomposing ability were selected. Lactic acid bacteria that were assessed to have high purine-decomposing ability according to the above-mentioned selection were orally administered to rats reared on purine-containing feed, the general status and serum uric acid level of the rats were measured, and the effect of lactic acid bacteria administration on serum uric acid levels was examined. As a result, lactic acid bacteria that significantly suppress the increase of serum uric acid levels, Lactobacillus gasseri OLL2922, were found.

The invention provides lactobacillus gasseri and application thereof for preparing vaginal bacteriostatic drugs. The lactobacillus gasseri is collected in China General Microbiological Culture Collection Center, and has a collection number of CGMCC No. 14109. Study of metabolic performance of the lactobacillus gasseri discovers that, compared with ordinary lactobacillus gasseri, the strain has high lactic acid and hydrogen peroxide production capacity, is excellent in bacteriostatic ability of pathogenic bacteria, and also has outstanding vaginal epithelial cell adhesion ability. Based on theprevious discovered novel properties, the invention further provides application of the lactobacillus gasseri in preparation of vaginal bacteriostatic drugs, so that treatment of multiple bacterial vaginal diseases can be realized. The bacterium agent disclosed by the invention has obvious effects on the bacterial vaginal diseases and is safe, non-toxic, excellent in stability and capable of beingpreserved for a long time. The invention further relates to application of the lactobacillus gasseri in medicines for preventing and/or treating gynecological diseases.

The invention discloses novel lactobacilli and a composition thereof, and an application thereof in preparing medicines used for ameliorating diabetes and complications thereof. The composition comprises an effective amount of at least one lactobacillus selected from: lactobacillus reuteri GMNL-89, lactobacillus gasseri GMNL-205, and lactobacillus reuteri GMNL-263; and a pharmaceutically acceptable carrier. The lactobacillus gasseri GMNL-205 and the lactobacillus reuteri GMNL-263 are novel lactobacilli. The composition and novel lactobacilli provided by the invention have novel applications for ameliorating diabetes and complications thereof.

The present invention relates to four kinds of lactobacilli, including Lactobacillus gasseri with preservation number of CGMCC No. 0840, Lactobacillus reuteri with preservation number of CGMCC No. 0841, Lactobacillus acidophilus with preservation number of CGMCC No. 0842 and Lactobacillus fermentum with preservation number of CGMCC No. 0843, separated from piglet intestinal tract and bred. The combination of the four kinds of lactobacilli is used in preparing the probiotics preparation for preventing and treating piglet ablactation diarrhoea and promoting growth, and the probiotic preparation is added into feed for ablactated piglet to prevent and treating diarrhoea and promote its growth.

The invention relates to the field of infant foods and in particular relates to a probiotics composition as well as an application and infant food thereof. The probiotics composition is prepared from bifidobacterium HN019 and lactobacillus rhamnosus HN001. With the adoption of the infant food, the content of the bifidobacterium and the content of the lactobacillus rhamnosus in intestinal canals of infants can be remarkably increased, the content of bacillus perfringens is remarkably lowered, and the micro-ecological environments of the intestinal canals of the infants are effectively improved; the content of acetic acid and the total content of short-chain fatty acid in faeces of the infants can be remarkably increased, and approach to those of the infants fed by pure breast milk; the content of sIgA (secretory immunoglobulin A) in the faeces of the infants can be remarkably increased, and approach to that of the infants fed by pure breast milk; the eczema occurrence rate of the infants can be remarkably lowered.

The invention relates to a probiotic composition, and discloses a probiotic composition beneficial for a glycolipid metabolic function and a preparation and application of the composition. The probiotic composition comprises some of the following nine probiotics: bifidobacterium longum, bifidobacterium breve, lactobacillus gasseri, lactobacillus rhamnosus, lactobacillus salivarius, lactobacillus crispatus, lactobacillus plantarum, lactobacillus fermentum and lactobacillus casei. Different strains in the probiotic composition cooperate with each other, so that the probiotic composition has thefunction of adjusting glycolipid metabolism, and has certain effect on serum total cholesterol, triglycerides, insulin beta-cell functions and diabetes mellitus improvement.

The invention discloses novel lactacidophilus, a composition thereof and use thereof in preparation of medicines for relieving diabetes mellitus and diabetic complications. The composition comprises at least one lactacidophilus which may be lactobacillus reuteri CMNL-89, lactobacillus gasseri GMNL-205 and lactobacillusreuteri CMNL-263. The lactobacillus gasseri GMNL-205 and the lactobacillusreuteri CMNL-263 are novel lactacidophilus. The composition or novel lactacidophilus can be used for relieving symptoms of diabetes mellitus and diabetic complications.

The invention discloses a fermented composition of multiple probiotics and composite medicinal and edible fungi, and a preparation method and an application thereof. According to the invention, a composite polysaccharide extract is obtained by enzymolysis and extraction of various medicinal and edible fungi by using compound enzymes, and the extract is subjected to symbiotic fermentation by using multiple intestinal probiotics, such that a fermented composition is obtained. The invention also relates to an application of the fermented composition in preparing health-care products used for preventing and treating tumors. The medicinal and edible fungi adopted by the invention are any three or more than three selected from lucid ganoderma, agaricus blazei murill, shiitake, and flammulina velutipes. The fungi are subjected to crushing, soaking, and enzymolysis; and bifidobacterium and lactobacillus are added for fermentation. Through symbiotic fermentation with the intestinal probiotics, the molecular weight of medicinal and edible fungi composite polysaccharide is substantially reduced, tumor cell inhibiting activity is substantially improved, and inhibition effect is substantially improved.

The invention concerns the isolation of novel properties of lactic acid bacteria stains. Said novel properties are advantageously useful for preventing and treating cancer. More particularly, the invention concerns the use of lactic acid bacteria to facilitate induction of cell apoptosis of a cancer. The invention also concerns the use of lactic acid bacterial strains, such as Lactobacillus acidophilus and Lactobacillus casei in methods and compositions for preventing and treating cancer, in particular colon cancer.

The invention relates to the medicines for gynecopathy, in particular to gel for adjusting microecology in vaginas of women, solving the problem that the traditional gynecological lotion kills probiotics while killing pathogens, thus causing vaginal flora imbalance and low immunity and further causing repeated vaginitis. The gel comprises the following components according to mass concentration: 0.5-2% of Carbomer, 0.1-1% of soy peptide, 0.001-0.01% of isoflavone, 0.5-3.5% of carotene and 0.3-3% of tea tree oil. The gel achieves the aim of suppressing pathogens by promoting lactobacillus proliferation. At present, the products in the market aim to kill the bacteria but finally disturb normal flora balance. The gel increases the absolute number of the lactobacillus, a predominant bacterium, simultaneously reduces the pathogens, maintains the balance of microecology in vaginas and improves vaginal cleanliness and the immunity of the vagina mucosa, thus achieving the aims of preventing gynecological vagina inflammation and reducing the reoccurrence rate of gynecological vaginitis. Besides, the formula of the gel is pure vegetable protein, thus being safer than other bacteriostats and bactericides.

The present invention relates to a process for treating organic waste, which comprises the step of contacting an organic waste with one or more microorganisms from at least three of the following microorganism species: Bacillus sp. microorganisms, Pseudomonas sp. microorganisms, Bifidobacterium sp. microorganisms and Lactobacillus sp. microorganisms.When they are contacted under certainconditions, the organic waste is at least partly converted to organic fertilizer.

The invention discloses lactobacillus gasseri and application thereof in relieving and treating hyperuricemia, and belongs to the technical field of microorganisms. According to the lactobacillus gasseri CCFM1133 disclosed by the invention, the serum uric acid level of hyperuricemia mice and the xanthine oxidase (XOD) activity of serum and a liver can be reduced, and the occurrence of hyperuricemia and gout is reduced; the blood glucose and serum triglyceride (TG) level of a patient with hyperuricemia can be regulated, and the activity of liver catalase (CAT) and glutathione peroxidase (GSH-Px) is improved; expression of ileum ABCG2 is improved, and excretion of intestinal uric acid is promoted; and the intestinal short-chain fatty acid level is improved, and the health is promoted. The lactobacillus gasseri CCFM1133 disclosed by the invention can be used for preparing foods, functional foods or medicines, and has a wide application prospect.

The invention provides the application of lactobacillus in frozen meat preservation and simultaneously provides a new bacterial strain A71 of Lactobacillus plantarum with a preservation number of CGMCC No.2228. The bacterial strain has an excellent culturing characteristic, a fermenting liquid of the bacterial strain has an excellent bacterial restraining capacity and can be used in the field of food preservation, in particular to the frozen meat preservation.

The invention discloses a functional nutritional agent for regulating the disharmony of intestinal florae and enhancing immunity and a preparation method thereof. The functional nutritional agent is prepared from four traditional Chinese medicines of Szechwan tangshen root, largehead atractylodes rhizome, Indian buead and honey-fried licorice in a weight ratio of 2:2:2:1 and spirulina, wherein a weight ratio of the four traditional Chinese medicines to the spirulina is 1-6:1-6. The preparation method comprises the following steps of: concentrating decoction of the four traditional Chinese medicines, inoculating lactobacillus to the concentrated decoction, and fermenting to obtain fermentation liquor of four gentlemen decoction; performing ultramicro crushing on the spirulina, inoculating bifidobacterium and fermenting to prepare fermentation liquor of the spirulina; and mixing the fermentation liquor of the four gentlemen decoction and the fermentation liquor of the spirulina, centrifuging to remove thalli, inactivating enzyme and drying to obtain the functional nutritional agent. The functional nutritional agent can prevent and correct the disharmony of the intestinal florae and enhance immunologic function, and also can protect hematopoietic function and blood liquidity, balance the metabolism of trace elements and improve endocrine function, so the functional nutritional agent is suitable for crew who perform long-distance navigation on naval vessels or submarines.

The invention discloses a microbial agent for producing nonantigenic soybean meal and a preparation method thereof and belongs to the technical field of microorganism application. The microbial agent uses Bacillus subtilis strain WB117, Saccharomyces cerevisiae Meyenex Hansen strain WY238 and Lactobacillus sp. strain L1 as strains. The strains are prepared into single-strain microbial agents respectively through inoculation, fermentation and culture; and the single-strain microbial agents are blended according a weight ratio of 1-3:1-3:1-3 to form a composite microbial agent. The microbial agent ferments a soybean meal raw material so as to remove antigenic substance and anti-nutritional factors, reduce the toxic action of the soybean meal on livestock, promote digestion and absorption, and improve percentage of the soybean meal in feed and the nutritional value of the soybean meal. The microbial agent and the method can be popularized among and used in feed additive enterprises and livestock farms or peasant households.